These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17367811)

  • 1. Multiple sclerosis: disease biomarkers as indicated by pathophysiology.
    Berger T; Reindl M
    J Neurol Sci; 2007 Aug; 259(1-2):21-6. PubMed ID: 17367811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies as biological markers for pathophysiological processes in MS.
    Reindl M; Khalil M; Berger T
    J Neuroimmunol; 2006 Nov; 180(1-2):50-62. PubMed ID: 16934337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis.
    Menge T; Lalive PH; von Büdingen HC; Cree B; Hauser SL; Genain CP
    J Allergy Clin Immunol; 2005 Aug; 116(2):453-9. PubMed ID: 16083805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward biomarkers in multiple sclerosis: new advances.
    Lolli F; Rovero P; Chelli M; Papini AM
    Expert Rev Neurother; 2006 May; 6(5):781-94. PubMed ID: 16734525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapy of multiple sclerosis].
    Simó M
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):23-6. PubMed ID: 19731815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specificity and correlation with disease activity of cerebrospinal fluid osteopontin levels in patients with multiple sclerosis.
    Chowdhury SA; Lin J; Sadiq SA
    Arch Neurol; 2008 Feb; 65(2):232-5. PubMed ID: 18268193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype.
    Rovaris M; Barkhof F; Calabrese M; De Stefano N; Fazekas F; Miller DH; Montalban X; Polman C; Rocca MA; Thompson AJ; Yousry TA; Filippi M
    Neurology; 2009 May; 72(19):1693-701. PubMed ID: 19433744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-secreting cells in the central nervous system in an animal model of MS: Phenotype, association with disability, and in vitro production of antibody.
    Pachner AR; Brady J; Narayan K
    J Neuroimmunol; 2007 Oct; 190(1-2):112-20. PubMed ID: 17919740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions.
    Frohman EM; Filippi M; Stuve O; Waxman SG; Corboy J; Phillips JT; Lucchinetti C; Wilken J; Karandikar N; Hemmer B; Monson N; De Keyser J; Hartung H; Steinman L; Oksenberg JR; Cree BA; Hauser S; Racke MK
    Arch Neurol; 2005 Sep; 62(9):1345-56. PubMed ID: 16157741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CD8 T cell in multiple sclerosis: suppressor cell or mediator of neuropathology?
    Johnson AJ; Suidan GL; McDole J; Pirko I
    Int Rev Neurobiol; 2007; 79():73-97. PubMed ID: 17531838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current concepts of the cellular and molecular pathophysiology of multiple sclerosis.
    Greenstein JI
    Dev Neurobiol; 2007 Aug; 67(9):1248-65. PubMed ID: 17514718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients.
    Garg N; Zivadinov R; Ramanathan M; Vasiliu I; Locke J; Watts K; Lema J; Rajeswary J; Munschauer FE; Ambrus J; Weinstock-Guttman B
    J Neuroimmunol; 2007 Jul; 187(1-2):159-65. PubMed ID: 17512610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homogeneity of active demyelinating lesions in established multiple sclerosis.
    Breij EC; Brink BP; Veerhuis R; van den Berg C; Vloet R; Yan R; Dijkstra CD; van der Valk P; Bö L
    Ann Neurol; 2008 Jan; 63(1):16-25. PubMed ID: 18232012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies against light neurofilaments in multiple sclerosis patients.
    Bartos A; Fialová L; Soukupová J; Kukal J; Malbohan I; Pitha J
    Acta Neurol Scand; 2007 Aug; 116(2):100-7. PubMed ID: 17661795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiplexing approaches for autoantibody profiling in multiple sclerosis.
    Somers K; Govarts C; Stinissen P; Somers V
    Autoimmun Rev; 2009 Jun; 8(7):573-9. PubMed ID: 19393211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of immunoglobulins and B cells in multiple sclerosis: from pathogenesis to treatment.
    Antel J; Bar-Or A
    J Neuroimmunol; 2006 Nov; 180(1-2):3-8. PubMed ID: 16934338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Molecular biomarkers for prediction of multiple sclerosis relapse].
    Satoh J
    Nihon Rinsho; 2008 Jun; 66(6):1103-11. PubMed ID: 18540355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of biomarkers in multiple sclerosis.
    Bielekova B; Martin R
    Brain; 2004 Jul; 127(Pt 7):1463-78. PubMed ID: 15180926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [MSRV retrovirus and gliotoxin protein: potential biological markers in multiple sclerosis?].
    Perron H
    Ann Biol Clin (Paris); 1998; 56(4):427-38. PubMed ID: 9754278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of B cells and autoantibodies in multiple sclerosis.
    Archelos JJ; Storch MK; Hartung HP
    Ann Neurol; 2000 Jun; 47(6):694-706. PubMed ID: 10852535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.